PCR testing for TB could lead to significant hospital savings -- AACC outcomes study.
This article was originally published in The Gray Sheet
Executive SummaryPCR TESTING FOR TUBERCULOSIS: "HUGE" COST SAVINGS could be achieved through TB-negative patients sent home early because of faster diagnosis via polymerase chain reaction, according to preliminary data from an American Association for Clinical Chemistry outcomes study. The preliminary findings, which were based on an economic analysis of 54 patients tested for TB, were presented at the annual meeting of the AACC in Anaheim, California on July 17 by Karen Kaul, MD, PhD, Evanston Hospital, Evanston, Illinois.
You may also be interested in...
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
A reagent in a batch of COVID-19 tests shipped by the US Centers for Disease Control and Prevention to state laboratories “wasn’t performing consistently,” a top CDC official says, so the agency is reformulating it – slowing down the labs’ ability to use the diagnostic, which yielded inconsistent results when quality-tested. But waiting in the wings are commercial coronavirus test kits being developed by Qiagen and Cepheid; both firms say they’ll submit the kits to the FDA for emergency-use approval.
OIG will focus on successful drugs that have been repurposed as orphans, noting nine of the 10 top selling drugs have both orphan and non-orphan indications.